CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibitingRasactivation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependentMMPswith IC₅₀s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyteapoptosisvia the NF-κB/HIF-2α axis^[1][2][3].

CMC2.24 (0-60 μM; 24 hours) inhibits pancreatic cancer growth in vitro^[1].
CMC2.24 reduces STAT3^Ser727phosphorylation levels, induces mitochondrial reactive oxygen species and mitochondrial cell death in pancreatic cancer cells. CMC2.24 induces mitochondrial reactive oxygen species and intrinsic apoptosis^[1].

CMC2.24 (50 mg/kg; p.o.; five times per week during 17 days) inhibits the growth of pancreatic cancer xenografts^[1].
CMC2.24 inhibits the growth of human PC through a strong cytokinetic effect. CMC2.24 inhibits ERK signaling pathway in PC cells and xenografts^[1].

427.45

Solid

C₂₆H₂₁NO₅

1255639-43-0

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

DMSO :< 1 mg/mL(insoluble or slightly soluble)